Hints and tips:
Related Special Reports
Related Topics
...Wells Fargo has hired Barclays’ telecommunications investment banker David Kase in New York, according to Bloomberg....
...The speakers included David Katz, a partner at New York law firm Wachtell, Lipton, Rosen & Katz, which has a reputation for representing companies against shareholder activists....
...Eurazeo’s largest shareholders are the Decaux family and the David-Weill family....
...The dividend is likely at the heart of what Peltz and his fellow billionaire, Marvel chair Ike Perlmutter, were hoping to secure from Disney. “This was a great win for all the shareholders....
...There was a personal story why Nelson Peltz got into it involving Ike Perlmutter, who was the Marvel chairman. He was on the inside of Disney, but he's very good friends with Nelson Peltz....
...Additional reporting by David Crow in New York...
...Part of the reason was that Dr Holman already knew Merck’s top scientist, Roger Perlmutter, one of the longest-serving heads of research and development in the industry....
...Dr Perlmutter said there was a “stronger set of data” behind Keytruda, which could be a reflection of the fact that the two companies had designed their clinical trials differently....
...Roger Perlmutter, Merck’s most senior scientist, says he was “kind of stunned” by the results from the study....
...Dr Roger Perlmutter, Merck’s chief scientist, said the “unambiguous” results had exceeded the company’s expectations. “As a first-line treatment this is better than anything we know about.”...
...Roger Perlmutter, Merck’s top scientist, said the company would focus its future efforts on combinations where each of the drugs has been proven to work separately as a “monotherapy” before testing them...
...“We are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer’s disease,” said Dr Roger Perlmutter, president of Merck Research Laboratories...
...Roger Perlmutter, president of Merck Research Laboratories, said: “The improved responses seen with the Keytruda plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding...
...“We’ve been saying for decades, that the idea of classifying tumours by what they look like under a microscope is probably not sensible,” says Dr Roger Perlmutter, the most senior scientist at Merck & Co...
...Dr Roger Perlmutter, the top scientist at Merck, has little sympathy for laggard companies, arguing they should instead focus their efforts on unearthing new drugs or looking for biological clues that might...
...Dr Roger Perlmutter, Merck’s research and development chief, said it was “too early to say” what the results meant for the theory underpinning Alzheimer’s, pointing out that the drug had been tested in mild...
...However, it is unlikely that a single combination will provide a one-size-fits-all solution, according to Roger Perlmutter, Merck’s top scientist....
...“Accelerated approval has been used in those individuals who have an invariably fatal disease and for whom nothing is available,” said Roger Perlmutter, Merck’s top scientist, in a recent interview conducted...
...Dr Roger Perlmutter, Merck’s top scientist, said the findings from both studies showed that immunotherapies were “becoming foundational in the way that we treat cancer”....
...Dr Roger Perlmutter, Merck’s top scientist and the architect of the company’s precision medicine strategy, continued to defend the approach even as Bristol-Myers pulled ahead....
...“There’s a sense in the oncology community that immune manipulation may turn out to be an even more important intervention than chemotherapy was — maybe the most important ever,” says Roger Perlmutter, president...
...A British exit from the EU would isolate the country’s scientists and reduce its influence in medicine, global pharmaceuticals executives have warned, as David Cameron fights for a deal in time for a June...
...Mr Perlmutter called on the government and other advocacy groups to do more to reassure the public about the safety of vaccines....
...Roger Perlmutter, executive vice-president of Merck, said headline results from a study of 15,000 participants had shown “there was no imbalance in heart failure hospitalisations” for patients on Januvia...
...“There’s a growing sense in the oncology community that immune manipulation may turn out to be an even more important intervention than chemotherapy was — maybe the most important ever,” says Roger Perlmutter...
International Edition